The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it buy, with a mean price target of $3937. It reported earnings in this window, a natural checkpoint for the thesis.
Fujifilm Holdings 4901.T
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · FUJIFILM Holdings Corporation provides products and services in the fields of healthcare, electronics, business innovation, and imaging in Japan, the Americas, Europe, Asia, and internationally.
read at $3,401.00
Fujifilm Holdings holds its Markup at $3,401.00.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · screen not yet scored
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 12 days |
| Price | $3,401.00 |
| Valuation | 15.13 trailing · 14.66 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.37 |
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades at roughly a 1% discount to our $3,430.48 fair value, 6.80% revenue growth.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
| Revenue growth | 6.80% |
| Profit margin | 8.24% |
| Debt to equity | 26.72 |
| Analyst consensus | Buy · 13 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This security has not been fully scored against the values screen yet.
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 15.3% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 3.3% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 13.0% of assets, under the 49% limit. Pass
- Revenue purity Only 0.1% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Why it gives us pause
At 14.7x forward earnings, the price already runs ahead of the business. Our fair value sits at $3,430.48, below where it trades today.
| Forward P/E | 14.7x expensive even after accounting for its growth |
| Trailing P/E | 15.1x reasonably valued |
| Revenue growth | 6.8% slow but positive growth |
| Profit margin | 8.2% thin but positive margins |
| Return on equity | 7.7% a modest return on shareholder capital |
| Debt to equity | 0.27 minimal debt — a conservative balance sheet |
| Beta | 0.37 barely tracks the market's swings |
| Market cap | $4.07T |
The risks · The things to watch: its business and earnings are exposed to Japan and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & how to trade · wherever in the world you are
4901.T trades on TSE (the company is based in Japan). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it buy, with a mean price target of $3937. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it buy, with a mean price target of $3937.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (13 analysts) rates it buy, with a mean price target of $3937.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $3,055.00 | +15.3% | · | $1,153 | +15.3% |
| 2 months | $3,116.00 | +13.0% | · | $1,130 | +13.0% |
| 3 months | $3,020.49 | +16.6% | $35.00 | $1,177 | +17.7% |
| 6 months | $3,424.74 | +2.8% | $35.00 | $1,038 | +3.8% |
| 1 year | $3,102.76 | +13.5% | $70.00 | $1,157 | +15.7% |
| 2 years | $3,579.11 | -1.6% | $135.00 | $1,022 | +2.2% |
| 3 years | $2,749.90 | +28.0% | $185.00 | $1,348 | +34.8% |
| 5 years | $2,379.90 | +48.0% | $265.00 | $1,591 | +59.1% |
Historical returns from market close data. Past performance does not guarantee future results.